NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Raj Consumer Care Q2 FY27 PAT Drops 8.5% YoY to ₹1.40 Cr Despite 10.4% Revenue Growth
Raj Consumer Care (formerly Raj Oil Mills) reported Q2 FY27 revenue from operations of ₹44.42 crore, up 10.4% YoY from ₹40.24 crore in Q2 FY26. Profit after tax declined 8.5% YoY to ₹1.40 crore compared to ₹1.53 crore in the year-ago period, impacted by higher current tax expenses of ₹0.48 crore versus nil last year. Sequentially, revenue grew 24.9% from ₹35.57 crore and PAT increased 26.1% from ₹1.11 crore in Q1 FY27. The company also confirmed full utilization of ₹5.75 crore raised via preferential allotment toward repaying promoter/director borrowings with zero deviation.
உச்சம் நம்பிக்கை
என்ன மாறியதுRaj Consumer Care reported Q2 FY27 quarterly results showing sequential revenue recovery and confirmed utilization of ₹5.75 crore preferential funds for promoter debt repayment.
ஏன் இது முக்கியம்Demonstrates modest top-line growth, but thin net margins (~3.2%) highlight continued vulnerability to raw material volatility and rising tax costs.
Q2 FY27 Revenue: ₹4,441.57 லட்சம்Q2 FY27 PAT: ₹140.34 லட்சம்Material Cost % of Revenue: 84.3%Preferential Fund Utilised: ₹5.75 கோடிUnpaid Creditors / Deposits (NCLT): ₹52.98 லட்சம்
📅 குறுகிய காலம்Sequential improvement in revenue and profit should support the stock, though muted YoY bottom-line growth may limit upside.
📈 நீண்ட காலம்Limited; company operates on thin margins inherent to edible oil processing, though promoter debt reduction from warrant/equity proceeds marginally de-levers the balance sheet.
⚠ அபாய எச்சரிக்கைகள்
High raw material dependence (~84% of revenue)
Auditor emphasis of matter on ₹52.98 Lakhs unpaid operational creditors/deposits due to untraceable parties under NCLT resolution
Very high debt-to-equity baseline from past distress
👀 கவனிக்க வேண்டியவை
Track operating margin stability and raw material price movements over upcoming quarters, alongside the full conversion of remaining warrants.
Greenlam Q2 FY27: Chipboard Turns EBITDA Positive at ₹6.8 Cr; H1 PAT Rises 184% to ₹45.7 Cr
Greenlam Industries released its Q2 & H1 FY27 investor presentation, highlighting a sharp turnaround in its newly commissioned Panel & Allied (Chipboard) segment. Chipboard net revenue jumped 123.9% YoY to ₹107.0 crore in Q2 FY27 with EBITDA swinging to positive ₹6.8 crore (6.3% margin) from a loss of ₹14.1 crore in Q2 FY26. For H1 FY27, overall PAT surged to ₹45.7 crore from ₹16.1 crore in H1 FY26, driven by higher utilization across chipboard (61%) and plywood (46%). Net debt slightly reduced to ₹921.8 crore as of H1 FY27 compared to ₹940.1 crore in FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுGreenlam published its detailed operational and segment-level presentation for Q2 and H1 FY27.
ஏன் இது முக்கியம்Confirms the operational turnaround of the capital-intensive Naidupeta chipboard facility, which previously dragged down profitability via unabsorbed fixed costs and forex impact.
Chipboard Q2 FY27 Net Revenue: ₹107.0 கோடிChipboard Q2 FY27 EBITDA: ₹6.8 கோடிH1 FY27 PAT: ₹45.7 கோடிNet Debt (H1 FY27): ₹921.8 கோடிNet Debt to Net Worth: ~0.76x
📅 குறுகிய காலம்Market may view the positive operating EBITDA in chipboard favorably as early evidence of return on the heavy capex incurred over FY23-FY25.
📈 நீண்ட காலம்As utilization rates on newly commissioned chipboard (61%) and plywood (46%) scale further, operating leverage could significantly improve consolidated return ratios (ROCE improved to 9.6% in H1 FY27).
⚠ அபாய எச்சரிக்கைகள்
High leverage with net debt of ₹921.8 cr relative to TTM EBITDA and net worth
Foreign exchange volatility impacting realizations and margins
Laminate production volume dipped 18.3% YoY in Q2 FY27
👀 கவனிக்க வேண்டியவை
Track the ramp-up and margin sustainability of the chipboard plant toward its targeted FY27 full break-even, along with the completion of the 2.0 mn sheets laminate capex slated for Q4 FY27.
Master Components H1 FY27 Net Profit Rises 71% to ₹5.55 Cr; Revenue Up 61% to ₹59.14 Cr
Master Components reported standalone revenue from operations of ₹5,914.21 Lakhs (₹59.14 Cr) for the half-year ended September 30, 2026, marking a 60.7% growth compared to ₹3,679.78 Lakhs in H1 FY26. Standalone profit after tax surged 71.1% to ₹554.79 Lakhs (₹5.55 Cr) from ₹324.22 Lakhs in the prior-year period. Basic EPS for the half-year stood at ₹13.87, compared to ₹8.11 in H1 FY26. Additionally, the company entered into a 50% joint venture in Pramas Engineering Private Limited via an investment of ₹5 Lakhs, presenting consolidated results for the first time.
உச்சம் நம்பிக்கை
என்ன மாறியதுMaster Components announced strong H1 FY27 financial results and initiated consolidated reporting following the creation of a 50% joint venture in Pramas Engineering Private Limited.
ஏன் இது முக்கியம்The company demonstrated strong operational growth with over 60% top-line expansion and expanded profit margins, strengthening its balance sheet with net worth increasing to ₹42.03 Cr (share capital + reserves).
Standalone Revenue (H1 FY27): ₹5,914.21 லட்சம்Standalone PAT (H1 FY27): ₹554.79 லட்சம்Half-Year Basic EPS: ₹13.87Investment in JV (Pramas Engineering): ₹5 லட்சம்வர்த்தக வசூலிக்கவேண்டியவை: ₹2,568.96 லட்சம்
📅 குறுகிய காலம்Market sentiment should react positively to the 71% growth in net profit and healthy half-yearly EPS delivery.
📈 நீண்ட காலம்Sustained execution in plastic engineering components combined with operational rationalization from the planned Master Moulds amalgamation could expand scale over the medium to long term.
⚠ அபாய எச்சரிக்கைகள்
Sharp increase in trade receivables from ₹13.25 Cr (Sep 2025) to ₹25.69 Cr (Sep 2026), increasing working capital requirements
Execution and integration risks related to the ongoing amalgamation of Master Moulds Private Limited
👀 கவனிக்க வேண்டியவை
Track the progress of the pending Scheme of Amalgamation with Master Moulds Private Limited and observe working capital intensity, as trade receivables rose to ₹25.69 Cr as of September 30, 2026.
Ramco Cements Q2 FY27: Revenue Up 10% to ₹2,466 Cr, Standalone PAT Drops 49% to ₹38 Cr
The Ramco Cements reported a 10% YoY growth in standalone revenue to ₹2,465.84 Cr for Q2 FY27, backed by an 8% increase in cement sales volumes to 47.38 lakh tons. However, standalone PAT dropped 49% YoY to ₹38.18 Cr, hit by sharp power and fuel cost increases (up 36% YoY per ton) and a disputed mineral-bearing land tax in Tamil Nadu of ~₹33 Cr. Standalone EBITDA declined 16% YoY to ₹330.54 Cr with EBITDA per ton contracting to ₹669/T from ₹866/T. For 1HFY27, revenue rose 10% to ₹4,742.02 Cr while PAT fell 56% to ₹70.04 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுRamco Cements published its 2QFY27/1HFY27 investor presentation showing volume-led top-line growth offset by severe fuel inflation and state tax levies.
ஏன் இது முக்கியம்Operating profitability is severely compressed (EBITDA/T at ₹669 vs ₹866), underscoring ongoing margin headwinds from energy costs and regional taxation despite steady volume demand.
2QFY27 Standalone Revenue: ₹2,465.84 கோடி2QFY27 Standalone PAT: ₹38.18 கோடி2QFY27 Standalone EBITDA: ₹330.54 கோடி2QFY27 EBITDA per Ton: ₹669 / TTN Mineral Land Tax Impact (2QFY27): ~ ₹33 Crores
📅 குறுகிய காலம்Margins will likely remain under pressure in the immediate term due to elevated imported fuel costs and volatile crude prices, despite modest price realizations (+1% QoQ).
📈 நீண்ட காலம்Company's volume positioning remains intact with steady expansion in non-cement lines (Construction Chemicals volume +38% YoY), but full-year recovery depends on resolution of state tax disputes and cooling power & fuel costs.
⚠ அபாய எச்சரிக்கைகள்
Severe fuel cost inflation (power and fuel cost per ton rose 36% YoY in Q2)
Regulatory risk via disputed mineral-bearing land tax in Tamil Nadu (~₹72 Cr impact in 1H)
👀 கவனிக்க வேண்டியவை
Monitor legal and regulatory outcomes concerning the disputed Tamil Nadu mineral-bearing land tax following the MMDR Amendment Act 2026, alongside crude/petcoke input price trends.
SMT's Irish Arm to Invest Up to USD 780,000 to Raise Stake in US-Based SNP Medical to 17.19%
Sahajanand Medical Technologies (SMT) announced that its wholly-owned subsidiary, SMT Ireland, will invest up to USD 780,000 in cash to increase its stake in Delaware-based SNP Medical Corp. SMT Ireland already held a 14.15% stake as of September 30, 2026, which will rise to up to 17.19% upon completion. SNP Medical is a medical device startup with 2025 revenue of USD 300,000, and the deal qualifies as a related party transaction because SMT promoter and director Priyanka Cohen serves as a director in SNP. The transaction is expected to conclude by March 31, 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுSMT's board approved an additional cash investment of up to USD 780,000 via SMT Ireland to hike its minority stake in SNP Medical Corp.
ஏன் இது முக்கியம்The deal provides product diversification in medical devices via an early-stage US startup, though it remains a small minority stake in a related-party entity.
📅 குறுகிய காலம்Limited stock price impact given the relatively small size of the investment and non-controlling stake.
📈 நீண்ட காலம்Provides exposure to US-based medical device R&D, but volatile revenues at the target entity mean near-term commercial contributions will be negligible.
Declining revenue trajectory at target entity (USD 564,930 in 2023 to USD 300,000 in 2025)
Early-stage development risk with minority non-controlling stake
👀 கவனிக்க வேண்டியவை
Track the final valuation determination per share and transaction closure by March 31, 2027, along with disclosures on product pipeline progress from the investee entity.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
R&B Denims Q2 FY27 Standalone PAT Falls 15% YoY to ₹3.91 Cr, Revenue Jumps 31% to ₹78.97 Cr
R&B Denims reported standalone revenue from operations of ₹78.97 Cr for Q2 ended September 30, 2026, up 31.3% YoY compared to ₹60.15 Cr in Q2 FY26. However, net profit for the quarter declined 15.0% YoY to ₹3.91 Cr from ₹4.60 Cr, squeezed by higher operating expenses and cost adjustments. On a sequential basis, revenue fell 3.2% QoQ from ₹81.62 Cr, while PAT dropped 30.9% QoQ from ₹5.66 Cr. For H1 FY27, net profit stood at ₹9.57 Cr on total revenue of ₹160.59 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுR&B Denims reported its Q2 and H1 FY27 financial results, reflecting top-line growth but contraction in net profit margins.
ஏன் இது முக்கியம்While demand generated higher revenue YoY, profitability suffered sequentially and annually, showing pressure on operating margins in the denim textiles business.
📅 குறுகிய காலம்Sequential margin decline may cause short-term pressure on the stock, which has already seen significant trailing-year corrections.
📈 நீண்ட காலம்Sustained execution on capacity investments (₹22.88 Cr in H1) and managing volatile cotton and input costs will determine long-term earnings trajectory.
⚠ அபாய எச்சரிக்கைகள்
Quarter-on-quarter and year-on-year margin contraction
Exposure to volatile cotton/raw material pricing in textile manufacturing
👀 கவனிக்க வேண்டியவை
Track operating margin stability and raw material cost pressures in upcoming quarters, along with returns generated on the ₹22.88 Cr capex deployed in H1.
Advenzymes Reports Q2 Revenue Up 16% YoY to ₹214.5 Cr, PAT at ₹51.2 Cr; Capex on Track
Advanced Enzyme Technologies held its Q2 FY27 earnings conference call, reporting consolidated revenue of ₹2,145 million (up 16% YoY and 12% QoQ) and PAT of ₹512 million (up 14% YoY). Operating EBITDA margins improved to 34% compared to 33% in Q2 FY26. Management announced the completion of its share buyback, repurchasing 2.41 million shares at an average price of ₹289.09 per share via the open market. For the full year, the company reaffirmed its capex guidance of ₹123 crore, of which approximately ₹52 crore was spent in H1.
உச்சம் நம்பிக்கை
என்ன மாறியதுAdvanced Enzyme released its Q2 FY27 earnings conference call transcript, elaborating on growth across segments and buyback completion.
ஏன் இது முக்கியம்Demonstrates sequential margin expansion to 34% and double-digit revenue growth despite raw material and power cost pressures.
Q2 FY27 Revenue: INR 2,145 millionQ2 FY27 PAT: INR 512 millionEBITDA லாப வரம்பு: 34%Shares Repurchased in Buyback: 2.41 மில்லியன்FY27 Capex Guidance: INR 123 கோடிCapex vs Net Worth: ~17.4%
📅 குறுகிய காலம்Sequential margin recovery to 34% and completion of the open market buyback provide stable operational support in the near term.
📈 நீண்ட காலம்Growth in Specialized Manufacturing and Biocatalysis segments along with planned ₹123 crore capex support its targeted medium-term 15% revenue CAGR.
⚠ அபாய எச்சரிக்கைகள்
Elevated power, fuel, and raw material costs
B2C venture (WELLFA) remains negligible and will take 2-3 years to scale
👀 கவனிக்க வேண்டியவை
Track the pace of revenue recovery in Human Healthcare and execution of the remaining ~₹71 crore capex planned for H2 FY27.
Chaman Metallics Posts H1 PAT of ₹11.92 Cr; Approves ₹100 Cr Rights Issue
Chaman Metallics reported a sharp operational turnaround for the half-year ended September 30, 2026, with revenue from operations surging 91.6% YoY to ₹376.58 Cr compared to ₹196.52 Cr in H1 FY26. Net profit turned positive at ₹11.92 Cr versus a loss of ₹2.55 Cr in the corresponding period of the previous year. Along with results, the board cancelled its prior Rights Issue proposal and approved a fresh fundraise of up to ₹100 Cr via a Rights Issue. The planned ₹100 Cr raise is massive relative to the company's net worth of ₹95 Cr (approx. 105%), indicating substantial equity expansion to deleverage or fund operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported strong turnaround to ₹11.92 Cr net profit for H1 FY27 and approved a fresh ₹100 Cr Rights Issue, cancelling the earlier proposal.
ஏன் இது முக்கியம்Higher capacity utilization drove top-line and profit expansion, but high finance costs (₹20.88 Cr) and heavy debt (₹440 Cr) make the ₹100 Cr equity infusion critical to repair the balance sheet.
H1 Revenue from Operations: ₹37,657.88 லட்சம்H1 Net Profit: ₹1,191.59 லட்சம்Proposed Rights Issue: Up to ₹100.00 CroresRights Issue vs Net Worth: ~105%H1 Finance Costs: ₹2,088.39 லட்சம்
📅 குறுகிய காலம்Positive reaction likely to the operational turnaround and profit rebound, though market attention will soon shift to the pricing and dilution impact of the ₹100 Cr Rights Issue.
📈 நீண்ட காலம்If successfully raised, the equity capital can help lower high leverage (D/E of 4.63) and finance costs, stabilizing earnings from expanded capacities.
⚠ அபாய எச்சரிக்கைகள்
High finance cost of ₹20.88 Cr for the half-year consuming significant operating profit
Equity dilution risk from the sizeable ₹100 Cr Rights Issue
High commodity cyclicality and dependence on steel realisations
👀 கவனிக்க வேண்டியவை
Monitor terms of the proposed ₹100 Cr Rights Issue including pricing, entitlement ratio, and record date, as well as management's planned use of proceeds toward debt reduction.
Mukta Arts Reports Q2 FY27 Results; Auditor Raises Ongoing Concerns on Subsidiaries
Mukta Arts approved its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The statutory auditors issued qualified conclusions regarding the carrying value of investments and loans in Whistling Woods International Limited (WWIL) totaling Rs 98.77 Cr, whose net worth is fully eroded amid ongoing High Court litigation. Additionally, subsidiary Mukta A2 Cinemas has accumulated losses of Rs 107.64 Cr with a net worth deficit of Rs 106.14 Cr, creating material uncertainty over its going concern status. WWIL reported quarterly revenue of Rs 15.73 Cr and a net loss of Rs 1.36 Cr for Q2.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved Q2 FY27 unaudited financial results accompanied by continued auditor qualifications on WWIL exposure and going-concern alerts for Mukta A2 Cinemas.
ஏன் இது முக்கியம்The Rs 98.77 Cr exposure to WWIL represents nearly 49% of Mukta Arts' net worth (Rs 201 Cr), posing significant write-down risks if pending legal proceedings resolve unfavorably.
Investment & loans in WWIL: Rs. 98,76,89,227WWIL exposure vs Net Worth: ~49.1%Mukta A2 Cinemas equity deficit: Rs. 10,614 lakhsMukta A2 Cinemas accumulated losses: Rs. 10,764 lakhsWWIL Q2 Revenue: Rs. 1,573 LakhsWWIL Q2 Net Loss: Rs. 136 Lakhs
📅 குறுகிய காலம்Market focus will remain on the persistence of auditor qualifications and severe equity erosion at key subsidiaries, keeping sentiment cautious.
📈 நீண்ட காலம்Resolution of the High Court dispute for Whistling Woods and successful capital restructuring of the Mukta A2 Cinemas chain remain critical to structural solvency.
⚠ அபாய எச்சரிக்கைகள்
Auditor qualification on Rs 98.77 Cr investment/advances in WWIL
Material uncertainty over going concern for subsidiary Mukta A2 Cinemas (equity deficit of Rs 106.14 Cr)
Pending litigation before the High Court with MFSCDCL
👀 கவனிக்க வேண்டியவை
Track High Court legal developments regarding the MFSCDCL rent/land dispute and monitor execution of the restructuring or strategic investment plan for Mukta A2 Cinemas.
Le Merite Q2 Standalone PAT Rebounds to ₹1.69 Cr; H1 Hurt by ₹12 Cr FVTPL Loss
Le Merite Exports reported standalone Q2 FY27 revenue from operations of ₹108.96 Cr, up 21.4% QoQ from ₹89.76 Cr and up 10.9% YoY. Standalone PAT turned positive to ₹1.69 Cr compared to a loss of ₹4.26 Cr in the preceding quarter, supported by a deferred tax credit of ₹1.03 Cr. For H1 FY27, the company incurred a loss of ₹3.65 Cr primarily due to a fair value loss of ₹12.02 Cr on investments measured at FVTPL. Operating cash flow remained under pressure with an outflow of ₹36.04 Cr for H1 FY27, driven by higher working capital lockup in receivables and loans.
உச்சம் நம்பிக்கை
என்ன மாறியதுLe Merite Exports approved Q2 and H1 FY27 financial results, marking a turnaround to net profit for the quarter despite drag from mark-to-market portfolio losses.
ஏன் இது முக்கியம்While operational revenue recovered QoQ, large non-operating fair value losses (₹12.02 Cr in H1) and negative operating cash flows remain a headwind against its small market cap of ₹41 Cr.
📅 குறுகிய காலம்Quarterly operational recovery back into profitability will offer some relief, but cash flow strain and investment portfolio volatility may cap positive sentiment.
📈 நீண்ட காலம்Structural improvement depends on sustained operating margins in textile trading and the successful commissioning and scaling of associate investments like Le Merite Torna Technical Textile Park.
⚠ அபாய எச்சரிக்கைகள்
Significant mark-to-market losses on current investments (₹12.02 Cr in H1)
Severe operating cash outflow of ₹36.04 Cr in H1 due to rising receivables and loans
Potential dilution from 26,30,000 equity shares underlying convertible warrants
👀 கவனிக்க வேண்டியவை
Monitor working capital normalization given the ₹36.04 Cr H1 operating cash burn, as well as the volatility arising from mark-to-market investments on profitability in subsequent quarters.
Q2FY27 Net Revenue Up 10% to Rs 2,466 Cr, EBITDA Drops 16% to Rs 331 Cr
The Ramco Cements reported a 10% YoY increase in standalone net revenue for Q2FY27 at Rs 2,466 crore, supported by an 8% rise in cement sales volume to 4.74 million tons. However, EBITDA declined 16% YoY to Rs 331 crore as EBITDA per ton contracted from Rs 866 to Rs 669 due to higher fuel costs and packing expenses. Profit before tax (including exceptional gains) halved to Rs 52 crore compared to Rs 100 crore in Q2FY26. Total debt edged up slightly to Rs 3,963 crore as of September 30, 2026, while capex guidance for FY27 was pegged at Rs 800 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுRelease of standalone un-audited financial results for Q2FY27 showing steady volume growth but significant operational margin contraction.
ஏன் இது முக்கியம்Higher fuel prices driven by geopolitical tensions in West Asia and currency depreciation severely offset volume gains, denting unit profitability.
Net Revenue: Rs.2,466 croresEBITDA: Rs.331 croresCement Sales Volume: 4.74 million tonsTotal Debt: Rs.3,963 croresFY27 Capex Guidance vs Net Worth: ~9.8% (Rs 800 cr / Rs 8,143 cr)
📅 குறுகிய காலம்Margin pressure is likely to weigh on sentiment over the near term as cost inflation from fuel and packaging outpaces pricing improvements.
📈 நீண்ட காலம்Capacity expansion towards ~31 MTPA by March 2027 and growth in higher-margin construction chemicals provide structural volume drivers once input cost volatility subsides.
⚠ அபாய எச்சரிக்கைகள்
Input cost inflation (power and fuel cost up 36% YoY to Rs 1,397/ton)
Disputed state levy (Tamil Nadu Mineral Bearing Land Tax paid under protest)
Elevated leverage with total debt at Rs 3,963 crore
👀 கவனிக்க வேண்டியவை
Track the commissioning of the 3.15 MTPA Kolimigundla clinkering unit scheduled for Dec-26, alongside movements in imported petcoke/fuel prices and resolution of the Tamil Nadu mineral tax dispute.
Q2 FY27 PAT Rises 8% YoY to ₹116 Cr; Loan Book Expands to ₹16,425 Cr
Repco Home Finance released its Q2 FY27 investor presentation reporting a net profit of ₹116 crore, up 8.4% YoY from ₹107 crore in Q2 FY26. Total income from operations stood at ₹481 crore compared to ₹445 crore in the prior year quarter. Total loan book reached ₹16,425 crore, reflecting 9.3% YoY growth over ₹15,033 crore as of September 2025. Asset quality improved meaningfully with Gross NPA falling to 2.42% compared to 3.16% a year ago, while Net NPA declined to 0.83% from 1.50%.
உச்சம் நம்பிக்கை
என்ன மாறியதுRepco Home Finance submitted its Q2 FY27 earnings presentation detailing operational and financial performance for the quarter ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates continued recovery in asset quality (GNPA at 2.42%) and steady loan book expansion, supporting stable net interest margins (5.5%) and healthy capital adequacy (37%).
Q2 FY27 Net Profit: ₹116 கோடிQ2 FY27 Revenue from Operations: ₹481 கோடிTotal Loan Book (Sep 2026): ₹16,425 கோடிDisbursements (Q2 FY27): ₹1,205 கோடிGross NPA: 2.42%நிகர NPA: 0.83%
📅 குறுகிய காலம்Stable performance with improving asset quality metrics may provide downside support to the stock following recent sector-wide softness.
📈 நீண்ட காலம்Consistent low credit costs and gradual AUM expansion towards historical targets (10-15% CAGR) remain key structural value drivers.
⚠ அபாய எச்சரிக்கைகள்
High cost-to-income ratio rising to 29.7% in Q2 FY27 from 28.4% in Q2 FY26
Non-salaried segment forms 53.6% of loan book, carrying higher underlying GNPA (3.2%) vs salaried (1.4%)
👀 கவனிக்க வேண்டியவை
Track whether disbursement growth momentum of >12% is maintained into H2 FY27 alongside further reductions in Stage-2 assets (currently at 7.0%).
Thermax Q2 FY27: Revenue Up 11% to ₹2,756 Cr, PAT Down 5% to ₹113 Cr; Order Book at ₹14,250 Cr
Thermax released its Q2 FY 2026-27 investor presentation, reporting an 11% YoY increase in operating revenue to ₹2,756 crore, driven by execution in Industrial Products and Industrial Infra segments. Profit after tax declined 5% YoY to ₹113 crore, hurt by unfavorable product mix, elevated raw material costs, and a ₹15 crore impairment provision in a hybrid renewable project. Order booking fell 8% YoY to ₹3,259 crore, but the overall order balance grew 16% YoY to a record ₹14,250 crore (~1.3x TTM revenue). Cash and investments stood robust at ₹3,260 crore, up 20% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுThermax disclosed its operational performance and detailed segment trends for Q2 FY 2026-27 via an investor presentation.
ஏன் இது முக்கியம்Demonstrates solid top-line execution and a large order backlog (1.3x TTM revenue), but reveals ongoing margin drag from commodity volatility, freight disruptions, and one-off project impairments.
Operating Revenue (Q2): ₹2,756 கோடிProfit After Tax (Q2): ₹113 கோடிOrder Balance: ₹14,250 கோடிOrder Balance vs TTM Revenue: ~131.5%Renewable Project Impairment: ₹15 கோடிCash & Investments: ₹3,260 கோடி
📅 குறுகிய காலம்Muted to range-bound price reaction expected as top-line expansion and solid order backlog are counterbalanced by a 5% drop in PAT and an 8% contraction in fresh order inflows.
📈 நீண்ட காலம்Structural tailwinds remain intact due to green transition offerings (biomass, green hydrogen purification, electric heat pumps) and exposure to expanding sectors like metals, cement, and data centers.
⚠ அபாய எச்சரிக்கைகள்
Input cost pressure from elevated steel and fuel prices
Supply chain delays and freight spikes linked to Middle East tensions
Project impairment risk in renewable energy assets (₹15 crore in Q2)
👀 கவனிக்க வேண்டியவை
Track margin recovery in the Industrial Products division and execution of the ₹14,250 crore order backlog over the next 2-3 quarters, especially amidst elevated input costs and geopolitical supply chain pressures.
RMCL Q2 FY27 Reports Profit of ₹0.41 Mn on Zero Core Revenue; Total Equity at ₹4.02 Mn
Radha Madhav Corporation reported standalone net profit of ₹0.41 million (₹0.041 crore) for the quarter ended September 30, 2026, compared to a net loss of ₹7.50 million in the preceding quarter. Revenue from core operations remained at zero, with total income driven entirely by other income of ₹3.31 million. Total expenses decreased sharply to ₹2.90 million from ₹10.09 million in Q1 FY27, mainly due to lower other expenses. The company's balance sheet remains fragile, with negative other equity of ₹(74.08) million leaving total equity at just ₹4.02 million against liabilities of ₹142.92 million.
உச்சம் நம்பிக்கை
என்ன மாறியதுRMCL posted a marginal net profit of ₹0.41 million in Q2 FY27 after reporting losses in preceding periods, driven by cost curtailment and other income.
ஏன் இது முக்கியம்Operational activity remains completely halted with zero revenue, meaning profits are supported strictly by non-operating income while net worth remains severely eroded.
Revenue from operations: NilOther Income (Q2 FY27): Rs. 3.31 millionNet Profit (Q2 FY27): Rs. 0.41 millionTotal Equity (as of Sep 2026): Rs. 4.02 millionTotal Liabilities (as of Sep 2026): Rs. 142.92 million
📅 குறுகிய காலம்Trading window opens November 09, 2026; however, market reaction is likely subdued given the lack of core business operations.
📈 நீண்ட காலம்Limited viability unless the company revives its core operating model and addresses its negative other equity and liability burden.
⚠ அபாய எச்சரிக்கைகள்
Zero operational revenue
Severe net worth erosion with other equity at ₹(74.08) million
Reliance on other income for survival
👀 கவனிக்க வேண்டியவை
Track whether the company can restart commercial operations to generate operational revenue, and monitor updates regarding resolution of stressed liabilities.
Repco Home Declares ₹5/Share Interim Dividend; Fixes Record Date as Nov 13, 2026
Repco Home Finance has declared an interim dividend of ₹5 per equity share (50% on ₹10 face value) for FY 2026-27. The Board has fixed Friday, November 13, 2026, as the record date for determining eligible shareholders. Alongside this, the Board approved unaudited financial results for Q2 and H1 FY27, where standalone Q2 PAT stood at ₹115.86 crore compared to ₹106.94 crore in Q2 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுRepco Home Finance announced a ₹5 per share interim dividend and fixed November 13, 2026 as the record date.
ஏன் இது முக்கியம்Represents direct cash return to shareholders with an aggregate payout of approximately ₹31.28 crore on 6.256 crore shares, supported by quarterly net profit of ₹115.86 crore.
Interim Dividend per share: Rs.5ரெக்கார்ட் தேதி: 13-நவ.-2026Standalone Net Profit (Q2 Sep 2026): 115.86 crTotal Income (Q2 Sep 2026): 467.90 cr
📅 குறுகிய காலம்The stock will likely see trading interest around the ex-dividend date leading up to November 13, 2026.
📈 நீண்ட காலம்Limited; dividend payout aligns with routine capital return policies backed by stable quarterly earnings.
👀 கவனிக்க வேண்டியவை
Investors should track the ex-dividend date prior to November 13, 2026, to be eligible for the ₹5 per share payout, alongside reviewing the detailed Q2 asset quality metrics.
Madhavbaug Posts H1 FY27 Net Loss of ₹1.60 Cr vs Profit of ₹3.22 Cr YoY; Revenue Dips to ₹46.36 Cr
Vaidya Sane Ayurved Laboratories reported standalone revenue from operations of ₹46.36 crore for the half year ended September 30, 2026, down 1.75% from ₹47.19 crore in H1 FY26. The company swung to a net loss of ₹1.60 crore from a profit of ₹3.22 crore in the corresponding previous period, largely driven by a sharp jump in other expenses to ₹26.59 crore (up from ₹19.50 crore). Diluted EPS slipped into negative territory at -₹1.52 compared to ₹1.41 in H1 FY26. Short-term borrowings also expanded sharply to ₹11.82 crore as of September 30, 2026, compared to ₹2.59 crore at the end of March 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its unaudited standalone and consolidated H1 FY27 results, swinging from profit to a net loss alongside an increase in short-term borrowing levels.
ஏன் இது முக்கியம்Higher operating expenses and elevated marketing costs directly compressed profitability, reversing recent positive earnings momentum despite a low debt base.
📅 குறுகிய காலம்Negative sentiment is likely over coming weeks as investors digest the swing into net losses and an increase in working capital debt.
📈 நீண்ட காலம்Long-term trajectory depends on stabilizing customer acquisition unit economics, successfully commercializing Madhavprash, and driving higher clinic utilization.
⚠ அபாய எச்சரிக்கைகள்
Surge in other expenses eroding operating margins
Significant rise in short-term borrowings from ₹2.59 cr to ₹11.82 cr
Auditor noted unverified MSME classification and lack of provision for potential delayed-payment interest
👀 கவனிக்க வேண்டியவை
Track the drivers behind the surge in other expenses (such as digital customer acquisition spend) and monitor whether clinic utilization recovers to stem further operating losses in H2 FY27.
Simbhaoli Sugars CoC Extends Resolution Plan Submission Deadline to Nov 21, 2026
Simbhaoli Sugars announced that its Committee of Creditors (CoC) held its 5th meeting on November 04, 2026. The CoC approved an extension for submitting Corporate Insolvency Resolution Process (CIRP) resolution plans from November 05, 2026, to November 21, 2026. Additionally, the CoC received updates regarding ongoing cane allocation appeals before the Allahabad High Court alongside general operational matters. The company has been under insolvency since July 11, 2024, weighed down by Rs 1,011 Cr in debt and negative net worth.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe CoC extended the deadline for prospective bidders to submit resolution plans by 16 days to November 21, 2026.
ஏன் இது முக்கியம்The company carries Rs 1,011 Cr of debt against a market capitalization of just Rs 25 Cr; resolution plans will dictate whether equity survives, is substantially diluted, or gets extinguished.
Original submission deadline: 05th நவம்பர் 2026Revised submission deadline: 21st நவம்பர் 2026Total Debt vs Market Cap: ~40.4x
📅 குறுகிய காலம்Trading will remain highly volatile and driven by updates around resolution plan submissions and Allahabad High Court cane allocation hearings.
📈 நீண்ட காலம்Existing equity holders face significant dilution or cancellation risks depending on the structure of any eventual NCLT-approved resolution plan.
⚠ அபாய எச்சரிக்கைகள்
Severe insolvency risk under CIRP
Potential total loss or deep dilution of equity capital
Negative net worth of Rs -76 Cr with debt of Rs 1011 Cr
👀 கவனிக்க வேண்டியவை
Monitor whether prospective resolution applicants submit bids by the revised November 21, 2026 deadline and watch for subsequent evaluation by the CoC.
Innomet H1 FY27 Concall: Revenue Reaches ₹55.7 Cr, Order Book at ₹36.7 Cr
Innomet Advanced Materials submitted its H1 FY27 earnings call transcript, reporting revenue of ₹55.7 crore, more than doubling from ₹23.5 crore in the prior period. EBITDA margin recovered to 14.8% (EBITDA of ₹8.24 crore) from 4.4% in H2 FY26, with PAT reaching ₹4.75 crore. Growth was led by exports, which rose to 46% of revenue (₹26 crore), and a sixfold surge in tungsten heavy alloys to ₹17.6 crore. Management noted an unexecuted order book of ₹36.7 crore, aiming to reach ₹100 crore in annual revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுInnomet released the full management transcript for its H1 FY27 earnings call held on November 3, 2026.
ஏன் இது முக்கியம்Provides granular operational context behind the sharp revenue expansion, margin recovery, Swastik Tungsten integration (57.5% stake), and export mix shifts.
📅 குறுகிய காலம்Investors will review management commentary on order execution, raw material cost stabilization, and the Swastik Tungsten ramp-up.
📈 நீண்ட காலம்Long-term scaling depends on global supply chain shifts away from China in tungsten products, aerospace customer additions, and expansion into semiconductor-grade materials.
⚠ அபாய எச்சரிக்கைகள்
Volatile global tungsten raw material prices
Client concentration in specialized defense and export markets
High long-term revenue targets (₹1,000 cr) requiring new, unfinalized opportunities
👀 கவனிக்க வேண்டியவை
Track execution of the remaining ₹36.7 crore order book to verify the full-year ₹100 crore target, along with tungsten price volatility impacts on EBITDA margins.
Deem Roll Tech Reports H1 FY27 Results; Auditor Notes Rs 35.44 Lakh Unprovided Receivables
Deem Roll Tech Limited released its unaudited standalone financial results for the half year ended September 30, 2026. The company's total assets and liabilities stood at Rs 16,081.57 lakhs, up from Rs 14,534.16 lakhs in the previous period, with net worth increasing to Rs 8,900.32 lakhs. Short-term borrowings rose to Rs 3,203.46 lakhs from Rs 2,895.17 lakhs, while inventories increased to Rs 5,565.27 lakhs. Notably, the statutory auditor highlighted an emphasis of matter regarding unprovided doubtful trade receivables of Rs 35.44 lakhs outstanding for over a year.
உச்சம் நம்பிக்கை
என்ன மாறியதுDeem Roll Tech declared its half-yearly financial results for the period ended September 30, 2026, alongside an auditor review report.
ஏன் இது முக்கியம்Provides an update on the company's balance sheet health, working capital expansion, and auditor observations on asset recoverability.
📅 குறுகிய காலம்Market reaction is likely to remain muted given the routine nature of the half-yearly report, though the auditor's emphasis of matter warrants notice.
📈 நீண்ட காலம்Long-term performance hinges on stabilizing newly added manufacturing capacities, expanding export market share, and controlling working capital debt.
⚠ அபாய எச்சரிக்கைகள்
Auditor emphasis of matter on non-provision of Rs 35.44 lakhs in doubtful trade receivables over one year old
Rising short-term debt and inventory buildup
👀 கவனிக்க வேண்டியவை
Track recovery of the Rs 35.44 lakh aged receivables and monitor working capital trends given the inventory buildup in H2 FY27.
MOLBIO Q2 FY27 Net Profit Drops 93% YoY to ₹7.7 Cr on Revenue Deferral
Molbio Diagnostics released its Q2 FY27 investor presentation, reporting a 54% YoY drop in total income to ₹264.8 crore and a sharp 93% YoY drop in PAT to ₹7.7 crore. Management attributed the weakness to rate-contract negotiations taking 1-1.5 months, meaning Q2 did not reflect a full three months of sales. For H1 FY27, total income stood at ₹676.3 crore compared to ₹681.8 crore in H1 FY26, with PAT falling 27% to ₹60.4 crore. Despite the soft quarter, management maintained its guidance of 25% topline growth for full-year FY27, noting that H1 historically represents only 35-45% of annual revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுMolbio reported subdued Q2 FY27 operational numbers due to prolonged rate-contract negotiations that stalled sales for 1-1.5 months.
ஏன் இது முக்கியம்Operating deleverage severely hit Q2 margins (EBITDA margin fell to 18.8% vs 29.0% YoY), putting pressure on H2 execution to meet annual guidance.
📅 குறுகிய காலம்Negative earnings shock in Q2 is likely to weigh on sentiment, although cash flow improvement and seasonal H2 back-ending offer some relief.
📈 நீண்ட காலம்Expansion into veterinary diagnostics (6 new assays in progress) and growing recurring kit sales (~74% of FY26 product revenue) support structural expansion if institutional tenders normalize.
⚠ அபாய எச்சரிக்கைகள்
Lumpy institutional revenue dependent on rate contract timelines
Steep ask in H2 FY27 to achieve guided 25% annual revenue growth
👀 கவனிக்க வேண்டியவை
Track whether Q3 FY27 shows a sharp revenue catch-up following concluded rate contracts to validate management's 25% FY27 growth target.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
